David Kaysen has stepped down as president and CEO of Uroplasty. Robert Kill, an independent director and former executive at Baxter, has been tapped to serve as CEO on an interim basis.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||